financial again business first today Thank provide as Good once an and highlights time our the results. overview thank everyone, Victor. taking XXXX to recent and we quarter discuss you, you of afternoon, for join us
for Dr. Chief me call Officer; be financials. Q&A. our I'll to Andrew quarter corporate today Sims, our Mr. then then joining LaFrance first Joining us Dr. for the recent the and the over are Andrew Norman and turn call to Chief begin in call will clinical by our review Financial Medical and reviewing our progress LaFrance, Officer. the
highlighting Let specific programs. and diagnostic our me corporate begin discussing by updates before therapeutic some recent
X, So a May first which we financing up funding $XX.XX an to of consisted of placement of an million, of closed million initial private all, aggregate and $X.XX up upfront proceeds on of approximately XXXX, for from of to of accompanying election insiders. and cash an upon financing with the participation Management, Capital exercise investors.
The care-focused approximately included the at additional institutional investors LLC warrants $XX participation additional AIGH health million from
approval research pediatric FDA. grant Second, from of IND patients medical for award United The glioma the from and million I/II Department be we trial States a notice ependymoma Defense, used $X with Phase for a directed programs. received a to the will of congressionally award following high-grade fund
just sheet Phase that grant dilution. GBM NCI the had that out new preclinical grant specifically, from ongoing we to and indications had our minimizing funding technology I/II. and balance acquired the funding fund program a program through illustrates X-year More clinical we grant to to strategy this of reminder, use a the been when while impact or development external the found our initial support shareholder As to
years development. nearly our DoD grant continue We're And LM received for the subject therapeutic Second, technology, future. and that to today, management program award novel forward X continues this brain drive expertise $XX of strategy this our for cancer matter pediatric going to foreseeable funding from leverage to CPRIT. over strategy million with
PhD Finally, for our Andrew to and extensive Dr. and pivotal developing the Barbara related we CNS Brenner, Blouw MD-PhD with in tumor neuro-oncologist, clinical operations strategy, Blouw been has the strengthen planning to biology, clinical an and Dr. team rhenium experience team. biomarker in management for is cerebrospinal -- instrumental forthcoming obisbemeda our Brenner and added development is fluid. and a Dr. of neoplasms Dr. trials,
clinical I'll single trial Escalation in leptomeningeal of obisbemeda begin a Now for product I by X-year terms rhenium programs, our for on with nearly a Phase is basket Dose $XX from ReSPECT-LM CPRIT. This metastases. development award Trial our of funded updates million administration substantially
Cohort single enrollment During of of XX.X radiation at X announced millicuries. patients dose X, in the for dosing QX, we a required the
XX XXXX, of that patients the trial exceeded now continue well. to Multiple made have use have and clinicians the of compassionate XX do to doses data survivors March been follow-up patient remained most in available recent for dosed As period update alive. also
investigational enthusiasm participate that we patient and to and continues Recently, grow. will We follow-on and XXXX in at expect enrollment investigator the in to Denver.
Furthermore, present trial safety Phase trial an additional therapy August for data the for the subsequent high both in the meeting remains recruitment SNO/ASCO KOL X I updated trials. the and added and sites to
in at I that dose basket data trial the the this all Phase set of in a at then for enrollment SNO as the the the complete with will and Ultimately, full cohorts arm potentially cure I time to FDA they November LM. a regarding to approach from we the to in trial. parallel, the multi-dose optimal is goal Annual year of Houston.
In therapeutic and expansion obisbemeda Meeting dialogue of presently I Phase exist single be Our Phase present trial rhenium suppress XXXX are believe in we multiple doses
provide once finalized an update will is FDA the approval obtained. We plan is and
LM the which Additionally, in regarding of week, new fully currently -- the you expand when an from the you LM about recommended KOL highlights for tremendous focused a and The synergistic a be we planned as trial investigate intend have hosted on encourage we dose the pivotal that with than on obisbemeda advisers. which the can CNSide. recording opportunity call on I our orphan development to company. trial the is to called we and more We would to move will diagnostic Phase of initial cancer for the which II Rather FDA metastatic communications for pivotal focused or forward provide team with Phase towards like acquisition this our rhenium website FDA.
Last II/III revisiting found and today, LM. details platform designation to investor design learn of the be call our breast
for So here the the highlights. with key the begin X acquisition. the key I'll points are And rationale outlining
to a sensitivity. which lack in First include tough current is all, diagnostics, diagnostic make the of cytology, MRI Leptomeningeal and cancer state-of-the-art diagnosis
ReSPECT-LM we and assay in Second, firsthand trial the with our experience CNSide its developed saw value.
have come a to CNSide who game the have their engage multiple to practice. physicians assay Additionally, with KOL as see opportunity in changer we
autopsy significantly Third, indicate underdiagnosed. likely is studies LM
enhanced advantage obisbemeda an such, LM. patients for CNSide as As to take rhenium means more able therapy such diagnostics may of be
we develop, CNSide commercial the the in to commercialize a technology Finally, opportunity stand-alone near monetize is then term. substantial that and recognize there
that all of and our supporting essential analysis, exclusively tests. CNSide provide assets types CNSide on acquired and related to rationale this based we So X commercially, includes testing
First of CTC, which This the cell melanoma cancer the in or call enumeration CSFXX. and all, quantifies tumor cells testing, we circulating cell adenocarcinoma tumor CSF.
CSFXX guidance. hybridization situ cancer-specific we fluorescence and And validated clinically to of to cell-free testing, we in LM.
In endpoint is sequencing implemented analyzes or CSFXX today. called to DNA third, we our next-generation DNA XXXX, FISH acquired the acquisition, mutations therapeutic trial the call identify the expression use test genetic ReSPECT-LM obtained exploratory that QX related an CSFXX in that as determines for currently and it into we Second, the prior gene
part August to endpoint decision-making data the the of we acquisition, meeting its XXth XC that As last data, clinical the which week, evaluates of we LM. acquired in in full the SNO/ASCO its the therapeutic FORESEE and And met X presentation for the is disclosed clinical trial primary and Denver. planned CNSide addressing trial trial utility in
steps, in of availability will in the longer conjunction be expanding trial next time regime. to planned we in our forward our So multiple now looking the dosing with test terms ReSPECT of points
business complete reimbursement attention commercially a with We launching evaluation, are including of optimization the test as also the XXXX. a strategy QX soon finalizing as
that about website market tests commercial a last anticipate release As can X.X press acquisition And a total visiting in potential addressable with week's later a related to then opportunity finally, that plan talking our have diagnostic details. CNSide plan and partners more of the million investor and our over potential at finally, and are We business just parallel, expressed by of call, interest asset, we learn for the call reminder, at you CNSide.
And look in discuss the development annually growth. further the the date. additional discussed in to we
now trial rhenium with recurrent in shift gears respected So evaluating GBM our obisbemeda regarding patients and glioblastoma.
that's now enroll And to tumors less or greater X. XX to that. II and in escalation are I than I is patients cohort both patients ongoing in than with GBM continue and also tumors dose Phase Phase We that equal still GBM Phase milliliters with our
As in help we the that that new of to financial study, XXXX. and are set us NIH And able is as sites completion Phase I for work to NCI finish has supporter which enrollment for down the primary the Phase add III earlier, trial for this winding trial funding speed up the the will trial study. II mentioned we been
So AdventHealth.
These Dallas, State area, to XXXX key and pivotal the North a focused Lenox contribute University, second which to are half the the in the sites adding and the and new Shore in network York in in part [indiscernible] Upper enroll we in besides Hospitals, substantially Midwest, will New San our Texas of Antonio, X Houston now Ohio trial the and centers population X on are of trial. Florida, Hill Northwell to sites
enrollment designation We data on neurosurgery the neuro-oncology have for is complete ourselves of and We early will be in to final provide at or X meetings, complete this meeting these or degree determined. XXXX key timing new and a the a to that by participation be II significant set update plan to Phase enrollment the XXXX goal influenced to fall of sites.
terms Phase for far, standard care overall safety of of compared improvement OS reviewed to demonstrating reminder, a of over November has seen As efficacy, and approximately highly as the in date II XX% a the trial the months X in or promising and standard to thus in care. survival XX-month XXXX of data both
for the primary mentioned a the to of given upon delivery is amount there's As therapy improving external this beam leapfrog can all believe radiation also, tremendous last CNS point. I which standard safety we of radiation, opportunity the neoplasms, the to for profile our CNS radiation care in using essentially unprecedented means deliver at is a And broader GBM. of and quarter, we there the technology, potential
year trials, the and and opportunity potential in meet and scenes Phase Phase the are pivotal our design partners that to with to plans collaborate I trial this want the on pivotal continue GBM. in to and this share trial and II We our later our potential manner. to plan the to discuss Phase a II work also to of the finalize planning data explore strategy view with align to FDA In parallel behind focused the existing we
I you update on cancer Finally, our to pediatric brain program. would like briefly
enrollment that XXXX at Hospital obtain site noted finalizing high-grade agreed I IND at those. we details Lurie and the anticipate, of to of FDA our IND support, approval the are of we initiating Phase will on funding Children's discussion a perhaps with initial the next for with we final several Chicago. update rounds year Department children glioma on can trial and be pediatric ready the Once I in be provide and with As in based with Defense FDA trial also the U.S. call, We an begin beginning previous ependymoma. our will early upon,
XXX radio RNL-BAM. device next-generation our XXX embolic or alginate to respect or called bio-degradable with rhenium nanoliposome Now microsphere
be device, mentioned, not warranted the anticipate updates design future. system portfolio. more is in providing on decision from finalizing the and in that a near when As previously device-related now working are we expanding as device I that the hand, And drug.
With requirements BAM FDA feedback the will a regulated related IP quality the
devoting are both first for supply we is that out our is contemplate areas we are trials ready chain significant Finally, key as to have chain and build a current energy commercialization. both in supply Two needs reliable beginning follows: manufacturing ultimately to and capability. as GMP is redundant pivotal sufficient high-capacity although a near-term our for pivotal and focus XXXX, trials
X a demand projections third So in an our drug redundant rhenium for to product, obisbemeda collectively, through we partner existing and serving XXXX. standards.
This that of the selecting ensure complement we alternative addition, could the as are of that source GMP manufacturers our process will final meets fulfill
Second for additional radiation services area focus is capability.
enhancing we our to more to update. supply I'll well part providers, process are of commercial will intermediate and that exclusive report starting into manufacturing key we're need and of to currently radioisotope key as our products. able for supply, the network agreements Moreover, expand we process, and the a nonexclusive support drug So today, we both overall are
our We now scenario.
And Andrew? Andrew I'll the Sims, that, will Financial the any review guarantee Chief financials. demand to who call turn strategies reliable Officer, foreseeable under availability are refining also to with inventory-based over drug
